Eastern Bank grew its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.3% in the third quarter, HoldingsChannel reports. The fund owned 14,578 shares of the company’s stock after acquiring an additional 334 shares during the period. Eastern Bank’s holdings in Moderna were worth $974,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC acquired a new position in Moderna during the 2nd quarter valued at about $26,000. Cedar Wealth Management LLC grew its holdings in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the period. Westside Investment Management Inc. bought a new position in shares of Moderna during the 1st quarter valued at about $32,000. Family Firm Inc. acquired a new stake in shares of Moderna during the second quarter worth $33,000. Finally, Bank & Trust Co bought a new stake in shares of Moderna in the second quarter valued at about $36,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO James M. Mock sold 715 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,184 shares of company stock valued at $2,037,931 over the last 90 days. Company insiders own 15.70% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Report on MRNA
Moderna Price Performance
Shares of MRNA stock opened at $53.40 on Wednesday. The business has a fifty day simple moving average of $69.61 and a 200 day simple moving average of $103.90. Moderna, Inc. has a twelve month low of $52.81 and a twelve month high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a market cap of $20.47 billion, a P/E ratio of -3.41 and a beta of 1.66.
Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the prior year, the company posted ($3.62) EPS. The company’s revenue was down 29.9% on a year-over-year basis. On average, sell-side analysts forecast that Moderna, Inc. will post -9.85 EPS for the current fiscal year.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Stories
- Five stocks we like better than Moderna
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Dividend Capture Strategy: What You Need to Know
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.